<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045136</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000256377</org_study_id>
    <secondary_id>PONIARD-0102</secondary_id>
    <secondary_id>NEORX-0102</secondary_id>
    <secondary_id>FHCRC-1704.00</secondary_id>
    <nct_id>NCT00045136</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poniard Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer&#xD;
      cells and cause less damage to normal tissue. Combining chemotherapy and holmium Ho 166 DOTMP&#xD;
      with peripheral stem cell transplantation may allow the doctor to give higher doses of&#xD;
      chemotherapy and holmium Ho 166 DOTMP and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining holmium Ho 166 DOTMP with&#xD;
      melphalan and peripheral stem cell transplantation in treating patients who have multiple&#xD;
      myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the radiation absorbed dose of holmium Ho 166 DOTMP to the kidney in patients&#xD;
           with multiple myeloma, based on whole body gamma camera image data for comparison with&#xD;
           that obtained using an ICRP mathematical model.&#xD;
&#xD;
        -  Determine the average marrow dose of this drug in these patients using gamma camera&#xD;
           whole body counts in patients receiving this drug.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Compare marrow dose estimates determined from gamma camera whole-body counts and thyroid&#xD;
           uptake probe counts in patients receiving this drug.&#xD;
&#xD;
        -  Evaluate intra-patient variability of the uptake of this drug in the bone with repeat&#xD;
           tests.&#xD;
&#xD;
        -  Determine whether the biodistribution and dosimetry is influenced by administering this&#xD;
           drug as a bolus compared to a 15-minute infusion in these patients.&#xD;
&#xD;
        -  Compare the reduction in dose rate from the 15-minute infusion vs the bolus injection of&#xD;
           this drug to estimate the effect on kidney exposure in these patients.&#xD;
&#xD;
        -  Determine the renal transit time for each patient after bolus injection of this drug and&#xD;
           assess whether this information improves the dose estimate to kidney with the&#xD;
           mathematical model.&#xD;
&#xD;
        -  Determine whether there is correlation of renal transit time from technetium Tc&#xD;
           99m-diethylenetriaminepentaacetic acid (DTPA) with holmium Ho 166 DOTMP.&#xD;
&#xD;
        -  Determine the adverse events in patients receiving this drug.&#xD;
&#xD;
        -  Determine the efficacy of a targeted therapy dose of holmium Ho 166 DOTMP with melphalan&#xD;
           followed by autologous peripheral blood stem cell transplantation in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are entered into one of two cohorts.&#xD;
&#xD;
        -  Cohort A: Patients receive a diagnostic dose of holmium Ho 166 DOTMP IV over 15 minutes&#xD;
           on day 1 and then IV bolus on day 8.&#xD;
&#xD;
        -  Cohort B: Patients receive a diagnostic dose of holmium Ho 166 DOTMP IV over 15 minutes&#xD;
           on days 1 and 8.&#xD;
&#xD;
      After each diagnostic dose, patients in both cohorts also undergo gamma camera imaging of the&#xD;
      whole body on days 1 and 8.&#xD;
&#xD;
      Approximately 1-3 weeks later, patients in both cohorts who demonstrate adequate uptake of&#xD;
      the first diagnostic dose of holmium Ho 166 DOTMP into the bone marrow then receive&#xD;
      therapeutic holmium Ho 166 DOTMP IV over 15 minutes once between days -13 to -10 followed by&#xD;
      melphalan IV over 20-30 minutes once between days -10 to -1. Patients undergo autologous&#xD;
      peripheral blood stem cell transplantation on day 0.&#xD;
&#xD;
      Patients are followed monthly for 1 year and then every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 12 patients (6 per cohort) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>holmium Ho 166 DOTMP</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma (MM)&#xD;
&#xD;
               -  Patients with a prior diagnosis of monoclonal gammopathy of undetermined&#xD;
                  significance (MGUS) or smoldering myeloma are eligible if they progressed and met&#xD;
                  the criteria for diagnosis of MM&#xD;
&#xD;
          -  No non-secretory MM&#xD;
&#xD;
          -  No symptomatic MGUS, smoldering MM, or indolent MM&#xD;
&#xD;
          -  No solitary bone or extramedullary plasmacytoma&#xD;
&#xD;
          -  No immunoglobulin M myeloma&#xD;
&#xD;
          -  Prior induction therapy for myeloma required&#xD;
&#xD;
          -  Responding, stable, or progressive disease after induction therapy, or relapsed&#xD;
             disease&#xD;
&#xD;
          -  Candidate for autologous hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Prior stem cell mobilization with chemotherapy and growth factors according to&#xD;
             institutional procedures&#xD;
&#xD;
               -  Availability of at least 2,000,000 CD34+ cells/kg&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  SGPT no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  No clinical evidence of amyloidosis of the liver&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 45 mL/min&#xD;
&#xD;
          -  Renal ultrasound normal&#xD;
&#xD;
          -  No clinical evidence of amyloidosis of the kidney&#xD;
&#xD;
          -  No urinary obstruction in the renal pelvis, ureter, or bladder outlet by ultrasound&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction at least 50% with no evidence of amyloidosis by echocardiogram&#xD;
&#xD;
          -  No clinical evidence of amyloidosis of the heart&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
          -  No symptomatic cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV1, FVC, and DLCO at least 60%&#xD;
&#xD;
          -  No symptomatic pulmonary disease&#xD;
&#xD;
          -  No clinical evidence of amyloidosis of the lungs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No known allergy to vitamin C or bisphosphonates&#xD;
&#xD;
          -  No known hypersensitivity to technetium Tc 99m phosphorus radiopharmaceuticals (e.g.,&#xD;
             technetium Tc 99m-methylene diphosphonate)&#xD;
&#xD;
          -  No concurrent illness that would severely limit life expectancy&#xD;
&#xD;
          -  No symptoms, physical findings, or radiographic evidence of cord compression&#xD;
&#xD;
          -  No clinical evidence of amyloidosis of the autonomic nervous system or&#xD;
             gastrointestinal tract&#xD;
&#xD;
          -  No prior noncompliance in other studies&#xD;
&#xD;
          -  No other malignancy within the past 5 years except treated indolent skin cancers or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior stem cell or bone marrow transplantation&#xD;
&#xD;
          -  No concurrent maintenance therapy comprising interferon or thalidomide&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent maintenance therapy comprising dexamethasone&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior cumulative external-beam radiotherapy (EBRT) to more than 20% of bone marrow&#xD;
&#xD;
          -  No prior cumulative EBRT dose of 30 Gy or more to the spinal cord&#xD;
&#xD;
          -  No prior radiotherapy to the bladder&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents for MM&#xD;
&#xD;
          -  At least 4 weeks since other prior experimental therapies for any other condition&#xD;
&#xD;
          -  No bisphosphonates for at least 4 weeks before study, during study, and for at least&#xD;
             30 days posttransplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Jenkins</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poniard Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2009</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

